# A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

> **NCT06834789** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 132 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** AGN-151586
- **DRUG:** OnabotulinumtoxinA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06834789
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-18
- **Primary completion:** 2025-11-03
- **Final completion:** 2025-11-03
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834789, "A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06834789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*